Clinical trials
Congenital Hyperinsulinism trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 4 |
| 2010 | 1 |
| 2013 | 2 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 22 |
| Active, not recruiting | 3 |
| Unknown status | 3 |
| Recruiting | 3 |
| No longer available | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Available | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Hospital of Philadelphia | 3 |
| Diva De Leon | 3 |
| Zealand Pharma | 3 |
| Montefiore Medical Center | 2 |
| Rezolute | 2 |
| University of Alberta | 2 |
| University of Minnesota | 2 |
| Xeris Pharmaceuticals | 2 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Baylor College of Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Congenital Hyperinsulinism | 37 |
| Hypoglycemia | 15 |
| Hyperinsulinism | 12 |
| Insulinoma | 4 |
| Glucose Metabolism Disorders | 3 |
| Metabolic Diseases | 3 |
| Pancreatic Diseases | 3 |
| Anemia, Sickle Cell | 2 |
| Argininosuccinic Aciduria | 2 |
| Biotinidase Deficiency | 2 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.